import type { BlogArticle } from '../blog-types';

export const article: BlogArticle = {
  slug: "where-to-buy-vasopressin-research-guide",
  title: "Where to Buy Vasopressin (AVP): A Researcher's Sourcing Guide",
  description:
    "Vasopressin research sourcing: understanding AVP vs. desmopressin vs. terlipressin distinctions, purity requirements for V1/V2 receptor studies, what a complete vasopressin COA must document, and how to identify research-grade supply.",
  category: "Quality & Testing",
  readMinutes: 8,
  publishedAt: "2026-06-06",
  ogImage: "/og-image.jpg",
  body: [
    {
      type: "paragraph",
      text: "Arginine vasopressin (AVP), also called antidiuretic hormone (ADH), is a nonapeptide synthesized in the paraventricular and supraoptic nuclei of the hypothalamus and released from the posterior pituitary in response to plasma hyperosmolality and hypovolemia. As both a peripheral vasoconstrictor (via V1a receptors on vascular smooth muscle) and a renal water-reabsorbing hormone (via V2 receptors on collecting duct principal cells), AVP occupies a central position in fluid homeostasis research, cardiovascular stress physiology, and social neuroscience.",
    },
    {
      type: "paragraph",
      text: "Research use of vasopressin spans neuroendocrinology, septic shock models, social behavior studies, and basic osmotic regulation research — each of which has distinct purity requirements and protocol sensitivities. Sourcing research-grade AVP requires understanding the key structural distinctions between native AVP and its clinical analogs, what analytical verification is required, and where vendor quality gaps are most likely to appear.",
    },
    {
      type: "heading",
      text: "AVP vs. Desmopressin vs. Terlipressin: Critical Distinctions",
    },
    {
      type: "paragraph",
      text: "Native arginine vasopressin (Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2; MW 1084.24 Da) activates both V1 (vasopressor/social behavior) and V2 (antidiuretic) receptor subtypes. Its two key clinical analogs — desmopressin (DDAVP) and terlipressin — were engineered for receptor selectivity and extended half-life:",
    },
    {
      type: "list",
      items: [
        "Desmopressin (DDAVP): desamino-Cys1, D-Arg8-vasopressin — eliminates V1a vasopressor activity while enhancing V2 selectivity; ~10× longer half-life than AVP; used in antidiuretic and hemostatic research",
        "Terlipressin (Gly-Lys8-vasopressin): a prodrug with selective V1 agonism; used in hepatorenal syndrome and portal hypertension models",
        "Native AVP: equipotent at V1a and V2 with short plasma half-life (~10 minutes); required for studies where V1a-mediated vasopressor effects or social behavior endpoints are the research target",
      ],
    },
    {
      type: "paragraph",
      text: "These are not interchangeable compounds. A vendor who supplies desmopressin when native AVP is requested — or who cannot confirm the structural identity of the compound — creates an immediate validity problem for receptor subtype studies. Standard HPLC cannot distinguish between these analogs if the UV trace alone is interpreted; mass spectrometry identity confirmation is required.",
    },
    {
      type: "heading",
      text: "What a Complete AVP COA Must Include",
    },
    {
      type: "paragraph",
      text: "A certificate of analysis for research-grade arginine vasopressin should document all of the following, tied to a lot number matching the product vial:",
    },
    {
      type: "list",
      items: [
        "Lot number matching the vial label",
        "Compound identity: arginine vasopressin (8-L-arginine vasopressin), CAS 113-79-1",
        "Molecular weight: 1084.24 Da (free base); specify if supplied as acetate salt (~1084 + acetate equivalents)",
        "HPLC purity: ≥98% with chromatogram (retention time, peak area, UV at 220 nm, gradient method)",
        "Mass spectrometry: ESI-MS confirming [M+H]⁺ = 1085.2 Da, distinguishing AVP from desmopressin ([M+H]⁺ = 1069.2) and terlipressin ([M+H]⁺ = 1227.4)",
        "Disulfide bond confirmation: native AVP contains a Cys1-Cys6 disulfide; reduced (free-thiol) forms have significantly different receptor activity; MS/MS peptide mapping or Ellman's assay should confirm bridge formation",
        "Peptide content by elemental analysis or nitrogen combustion",
        "Endotoxin (LAL) testing if intended for in vivo use — vasopressin's vasopressor activity can confound sepsis model data if endotoxin is present",
        "Third-party laboratory name with verifiable contact information",
      ],
    },
    {
      type: "callout",
      text: "Disulfide integrity matters: Reduced (linear) AVP lacks the correct Cys1-Cys6 bridge and has dramatically attenuated receptor binding. A vendor who supplies partially reduced AVP will appear to provide pure material by HPLC but the compound will be biologically inactive at expected doses. Disulfide confirmation is non-optional for V1/V2 receptor studies.",
    },
    {
      type: "heading",
      text: "Active Research Domains",
    },
    {
      type: "paragraph",
      text: "Research applications for native AVP span multiple fields:",
    },
    {
      type: "list",
      items: [
        "Social neuroscience: V1a receptor distribution in the central nervous system mediates affiliative behavior, pair bonding, and aggression in rodent models; AVP intranasal or ICV administration is used to study social memory, dominance hierarchies, and paternal behavior",
        "Cardiovascular and septic shock models: V1a receptor activation produces vasoconstriction in septic shock models where vasodilatory hypotension is studied; AVP and terlipressin are comparison compounds in vasopressor research",
        "Osmotic regulation: V2 receptor studies use AVP to probe aquaporin-2 trafficking in collecting duct cell lines; diabetes insipidus models use AVP deficiency and AVP replacement protocols",
        "Stress physiology: HPA axis crosstalk between CRH and AVP is studied in anxiety and stress response models; AVP potentiates ACTH secretion independently of CRH in some stress contexts",
      ],
    },
    {
      type: "heading",
      text: "Storage and Stability",
    },
    {
      type: "paragraph",
      text: "AVP is a disulfide-containing nonapeptide with specific stability requirements:",
    },
    {
      type: "list",
      items: [
        "Lyophilized powder: store at -20°C in sealed vials; stable 24–36 months; protect from humidity — lyophilized peptides are hygroscopic",
        "Avoid oxidizing conditions: the Cys1-Cys6 disulfide is susceptible to over-oxidation to sulfinic/sulfonic acid derivatives which are biologically inactive; do not store reconstituted AVP exposed to air",
        "Reconstitute with 0.9% saline or PBS at pH 4–5 for maximum stability; acidic pH reduces disulfide oxidation during storage",
        "Reconstituted solution: use within 7 days at 4°C; peptide adsorption to syringe walls can be significant at low concentrations — add 0.1% BSA as carrier if working below 100 ng/mL",
        "Do not autoclave; AVP is heat-labile at temperatures above 60°C",
        "Typical vial size: 1 mg; reconstitute in 1 mL for 1 mg/mL working stock, then dilute for experimental concentrations",
      ],
    },
    {
      type: "heading",
      text: "Dosing Context for Research Protocol Design",
    },
    {
      type: "paragraph",
      text: "Published rodent model doses for AVP vary substantially by administration route and endpoint. Peripheral (IV/IP) vasopressor protocols in rat sepsis models typically use 0.001–0.04 U/kg/min infusion. Central (ICV) social behavior studies in mice use 10 pg–1 µg per administration. Intranasal protocols for social memory studies use 0.1–1 µg per nostril. Researchers should note that AVP's short peripheral half-life (~10 min) means infusion protocols and bolus protocols produce fundamentally different receptor engagement profiles — protocol design must specify route, dose, and administration timing relative to endpoints.",
    },
    {
      type: "heading",
      text: "Why Nexphoria for Vasopressin Research",
    },
    {
      type: "paragraph",
      text: "Nexphoria's arginine vasopressin is supplied as confirmed native AVP with lot-specific COAs that include HPLC purity (≥98%), ESI-MS identity confirmation distinguishing AVP from its clinical analogs, disulfide integrity confirmation, endotoxin testing for in vivo protocols, and third-party laboratory documentation. Every lot COA is publicly posted for independent verification.",
    },
    {
      type: "paragraph",
      text: "Cold-chain shipping is standard on every order. AVP's disulfide stability and peptide adsorption characteristics make temperature control during transit a practical necessity for maintaining compound activity from the point of synthesis to the researcher's freezer.",
    },
    {
      type: "callout",
      text: "For research use only. Arginine vasopressin is a regulated pharmaceutical compound outside the research context. All institutional and regulatory requirements for neuropeptide research must be met prior to use.",
    },
    {
      type: "divider",
    },
    {
      type: "disclaimer",
      text: "This article is intended for researchers and scientific professionals. All compounds referenced are for laboratory and preclinical research purposes only. Not for human consumption. Nexphoria does not provide medical advice.",
    },
  ],
};
